Method of treatment of Hypoxia Inducible Factor (HIF)-related conditions

Patent metadata

Field	Value
Publication number	US-9687530-B2
Application number	US-201514754883-A
Country	US
Kind code	B2
Filing date	Jun 30, 2015
Priority date	Jul 11, 2014
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

The present invention relates to methods of treatment of Hypoxia Inducible Factor (HIF)-related conditions, and in particular to methods of treatment of HIF-related conditions comprising the administration of a composition comprising transferrins.

First claim

The invention claimed is:

1. A method of treating a Hypoxia Inducible Factor (HIF)-related pathological condition in a patient in need thereof, wherein the HIF-related pathological condition is Middle Cerebral Artery occlusion (MCAo), comprising administering to the patient a composition comprising a therapeutically effective amount of transferrin, and wherein the transferrin is a mixture of apo-transferrin and holo-transferrin in a ratio from 99% Apo-Tf:1% Holo-Tf to 30% Apo-Tf:70% Holo-Tf.

2. The method of claim 1 , wherein the composition further comprises an iron chelator or prolyl hydroxylase domain-containing protein 2 (PHD2) enzyme inhibitor.

3. The method of claim 2 , wherein the iron chelator is selected from the group consisting of M30, deferoxamine (DFO), Deferasirox, deferiprone, deferitrin, L1NAll, CP363, CP502 and Ethylenediaminetetraacetic acid (EDTA).

4. The method of claim 2 , wherein the PHD2 enzyme inhibitor is selected from the group consisting of IOX2, IOX3 and dimethyloxallylglycine.

5. The method of claim 1 , wherein the patient is a transplant recipient of an organ.

6. The method of claim 5 , wherein the organ has been treated with the composition in preparation for the transplantation into the recipient.

7. The method of claim 6 , where the composition further comprises an iron chelator or prolyl hydroxylase domain-containing protein 2 (PHD2) enzyme inhibitor.

8. The method of claim 1 , wherein the condition is associated with ischemia or oxygen deprivation in the patient prior to surgery.

9. The method of claim 8 , wherein the ischemia is due to cardiac arrest, thrombotic clots, traumatic injury or stroke.

10. The method of claim 1 , wherein the condition is associated with interruption of blood flow during a surgical intervention in the patient.

11. The method of claim 1 , wherein the transferrin is recombinant.

12. The method of claim 1 , wherein the transferrin is modified by pegylation, glycosylation or polysialylation to extend its plasma half-life.

13. The method of claim 1 , wherein the composition further comprises an iron chelator.

Assignees

• Grifols Worldwide Operations Ltd

Inventors

• Ross David A
• Crumrine Ralph Christian

Classifications

• A61K31/16 Primary

  Amides, e.g. hydroxamic acids · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K31/426

  1,3-Thiazoles · CPC title

• A61K31/4412

  having oxo groups directly attached to the heterocyclic ring · CPC title

• A61K31/164

  of a carboxylic acid with an aminoalcohol, e.g. ceramides · CPC title